Top

Published in:

Open Access 24-02-2024 | Breast Cancer | REVIEW

An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients

Authors: Alessandra Fabi, Alessandro Rossi, Edoardo Mocini, Ludovica Cardinali, Valerio Bonavolontà, Cristina Cenci, Stefano Magno, Vittoria Barberi, Antimo Moretti, Zein Mersini Besharat, Giovanni Iolascon, Carlo Baldari, Elisabetta Ferretti, Andrea Botticelli, Ida Paris, Giovanni Scambia, Silvia Migliaccio

Published in: Current Oncology Reports | Issue 4/2024

Abstract

Background

Breast cancer (BC) treatment has recently been revolutionized by the introduction of newer targeted agents, that helped tailoring therapies around the single patient. Along with increased survival rates, a careful evaluation of diet, lifestyle habits, physical activity, emotional and psychological experiences linked to the treatment journey, is now mandatory. However, a true proposal for an omnicomprehensive and “integrative” approach is still lacking in literature.

Methods

A scientific board of internationally recognized specialists throughout different disciplines designed a shared proposal of holistic approach for BC patients.

Results

A narrative review, containing information on BC treatment, endocrinological and diet aspects, physical activity, rehabilitation, integrative medicine, and digital narrative medicine, was developed.

Conclusions

In the context of a patient-centered care, BC treatment cannot be separated from a patient’s long-term follow-up and care, and an organized interdisciplinary collaboration is the future in this disease’s cure, to make sure that our patients will live longer and better.

Trial Registration

NCT05893368: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer (PERGIQUAL). Registration date: 29th May 2023.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78–81. https://doi.org/10.1126/science.1260825.CrossRefPubMedPubMedCentral

Jiralerspong S, Goodwin PJ. obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34(35):4203–16.CrossRefPubMed

Pérez-Solis MA, Maya-Nuñez G, Casas-González P, et al. Effects of the lifestyle habits in breast cancer transcriptional regulation. Cancer Cell Int. 2016;13(16):7. https://doi.org/10.1186/s12935-016-0284-7.CrossRef

Fiocchetti M, Bastari G, Cipolletti M, et al. The peculiar estrogenicity of diethyl phthalate: modulation of estrogen receptor Α activities in the proliferation of breast cancer cells. Toxics. 2021;9:237.CrossRefPubMedPubMedCentral

Darbre PD. Endocrine disrupting chemicals and breast cancer cells. Adv Pharmacol. 2021;92:485–520.CrossRefPubMed

• Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine. Mol Biol Rep. 2022;49(10):10023–37. https://doi.org/10.1007/s11033-022-07571-2. (This study highlights the therapeuthic approach to breast cancer according to the various molecular subtypes. It describes also treatment sequences which are fundamental to plan the best treatment path for each patient.)CrossRefPubMed

Schmid P, Cortes J, Pusztai L, McArthur H, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21. https://doi.org/10.1056/NEJMoa1910549.CrossRefPubMed

Gianni L, Pienkowski T, Im Y-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. https://doi.org/10.1016/S1470-2045(16)00163-7.CrossRefPubMed

10.

von Minckwitz G, Huang C-S, Mano MS, Loibl S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. https://doi.org/10.1056/NEJMoa1814017.CrossRef

11.

Masuda N, Lee S-J, Ohtani S, Im Y-H, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59. https://doi.org/10.1056/NEJMoa1612645.CrossRefPubMed

12.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31. https://doi.org/10.1056/NEJMoa1703643.CrossRef

13.

Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68. https://doi.org/10.1016/j.annonc.2022.09.159.CrossRefPubMed

14.

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2022. https://doi.org/10.1016/S1470-2045(22)00694-5.CrossRefPubMed

15.

Cortes J, Rugo HS, Cescon DW, Im S-A, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26. https://doi.org/10.1056/NEJMoa2202809.CrossRefPubMed

16.

Emens LA, Adams S, Barrios CH, Diéras V, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–93. https://doi.org/10.1016/j.annonc.2021.05.355.CrossRefPubMed

17.

Swain SM, Miles D, Kim S-B, Im Y-H, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020. https://doi.org/10.1016/S1470-2045(19)30863-0.CrossRefPubMed

18.

Hurvitz SA, Hegg R, Chung W-P, Im S-A, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022. https://doi.org/10.1016/S0140-6736(22)02420-5.CrossRefPubMed

19.

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41. https://doi.org/10.1056/NEJMoa2028485.CrossRefPubMed

20.

Di Lauro V, Barchiesi G, Martorana F, et al. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open. 2022;7(6):100629. https://doi.org/10.1016/j.esmoop.2022.100629.CrossRefPubMedPubMedCentral

21.

Mertz S, Benjamin C, Girvalaki C, et al. Progression-free survival and quality of life in metastatic breast cancer: the patient perspective. Breast. 2022;65:84–90. https://doi.org/10.1016/j.breast.2022.07.006.CrossRefPubMedPubMedCentral

22.

Brown JC, Ligibel JA. Lifestyle interventions for breast cancer prevention. Curr Breast Cancer Rep. 2018;10(3):202–8. https://doi.org/10.1007/s12609-018-0281-z.CrossRefPubMedPubMedCentral

23.

Orman A, Johnson DL, Comander A, Brockton N. Breast cancer: a lifestyle medicine approach. Am J Lifestyle Med. 2020;14(5):483–94. https://doi.org/10.1177/1559827620913263.CrossRefPubMedPubMedCentral

24.

Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obs Gynecol. 2006;18:24–8.CrossRef

25.

De Cicco P, Catani MV, Gasperi V, Sibilano M, et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019;11(7):1514. https://doi.org/10.3390/nu11071514.CrossRefPubMedPubMedCentral

26.

Boltong A, Aranda S, Keast R, Wynne R, et al. A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS ONE. 2014;9:e103512.CrossRefPubMedPubMedCentral

27.

Buch K, Gunmalm V, Andersson M, Schwarz P, et al. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-a systematic review. Cancer Med. 2019;8:238–45.CrossRefPubMed

28.

Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, et al. Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors. J Clin Oncol. 2005;23:774–82.CrossRefPubMed

29.

Ee C, Cave A, Vaddiparthi V, Naidoo D, Boyages J. Factors associated with weight gain after breast cancer: results from a community-based survey of Australian women. Breast. 2023;S0960–9776(23):00012–7. https://doi.org/10.1016/j.breast.2023.01.012.CrossRef

30.

Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev. 2011;12(4):282–94. https://doi.org/10.1007/s12282-022-01355-z.CrossRefPubMed

31.

Wong RMY, Wong H, et al. The relationship between sarcopenia and fragility fracture-a systematic review. Osteoporos Int. 2019;30(3):541–53. https://doi.org/10.1007/s00198-018-04828-0.CrossRefPubMed

32.

World Cancer Research Fund/American Institute for Cancer Research. Diet, nutrition, physical activity and cancer: a global perspective. Continuous Update Project Expert Report 2018. Available at https://www.wcrf.org/wp-content/uploads/2021/02/Summary-of-Third-Expert-Report-2018

33.

Campbell JN, Barton C, Cutress RI, Copson ER. Impact of obesity, lifestyle factors and health interventions on breast cancer survivors. Proc Nutr Soc. 2023;82(1):47–57. https://doi.org/10.1017/S0029665122002816.CrossRefPubMed

34.

Meyer D, Pastor-Villaescusa B, Michel S, Hauner H, Hauner D. Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials. BMC Cancer. 2022;22(1):1187. https://doi.org/10.1186/s12885-022-10274-3.CrossRefPubMedPubMedCentral

35.

Lake B, Damery S, Jolly K. Effectiveness of weight loss interventions in breast cancer survivors: a systematic review of reviews. BMJ Open. 2022;12(10):e062288. https://doi.org/10.1136/bmjopen-2022-062288.CrossRefPubMedPubMedCentral

36.

Caprara G, Tieri M, Fabi A, et al. Results of the ECHO (Eating habits CHanges in Oncologic patients) survey: an Italian cross-sectional multicentric study to explore dietary changes and dietary supplement use, in breast cancer survivors. Front Oncol. 2021;11:705927. https://doi.org/10.3389/fonc.2021.705927. (eCollection 2021).CrossRefPubMedPubMedCentral

37.

• Porciello G, Montagnese C, Crispo A, Grimaldi M, Libra M, Vitale S, Palumbo E, Pica R, Calabrese I, Cubisino S, Falzone L, Poletto L, Martinuzzo V. Mediterranean diet and quality of life in women treated for breast cancer: a baseline analysis of DEDiCa multicentre trial. PLoS ONE. 2020;15(10):e0239803. https://doi.org/10.1371/journal.pone.0239803. (This study revealed that higher scores in the PREDIMED questionnaire, which investigates adherence to the mediterranean diet, were associated with better physical functioning and global quality of life. Conversely, lower scores were related to pain and insomnia symptoms.)CrossRefPubMedPubMedCentral

38.

Jochems HJS, Van Osch FHM, Bryan TR, et al. Impact of dietary patterns and the main food groups on mortality and recurrence in cancer survivors: a systematic review of current epidemiological literature. BMJ Open. 2018;8(2):e014530. https://doi.org/10.1136/bmjopen-2016-014530.CrossRefPubMedPubMedCentral

39.

Rossi RE, Pericleous M, Mandair D, Whyand T, Caplin ME. The role of dietary factors in prevention and progression of breast cancer. Anticancer Res. 2014;34(12):6861–75.PubMed

40.

Hardt L, Mahamat-Saleh Y, Aune D, Schlesinger S. Plant-based diets and cancer prognosis: a review of recent research. Curr Nutr Rep. 2022;11(4):695–716. https://doi.org/10.1007/s13668-022-00440-1.CrossRefPubMedPubMedCentral

41.

Jabbari M, Pourmoradian S, Eini-Zinab H, Mosharkesh E, Hosseini Balam F, Yaghmaei Y, Yadegari A, Amini B, Moghadam DA, Barati M, Hekmatdoost A. Levels of evidence for the association between different food groups/items consumption and the risk of various cancer sites: an umbrella review. Int J Food Sci Nutr. 2022;73(7):861–74. https://doi.org/10.1080/09637486.2022.2103523.CrossRefPubMed

42.

Yang J, Chung M, Park Y. Association of fermented products with risk of cancer recurrence and mortality among breast cancer survivors: a prospective cohort study. Nutr Cancer. 2023;12:1–11. https://doi.org/10.1080/01635581.2023.2186259.CrossRef

43.

• Sasanfar B, Toorang F, Mohebbi E, Zendehdel K, Azadbakht L. Dietary carbohydrate quality and risk of breast cancer among women. Nutr J. 2021;20(1):93. https://doi.org/10.1186/s12937-021-00752-y. (This is one of the first studies to highlight that not only quantity, but also quality of the carbohydrates assumed with diet may have a role in breast cancer incidence.)CrossRefPubMedPubMedCentral

44.

Freudenheim JL. Alcohol’s effects on breast cancer in women. Alcohol Res. 2020;40(2):11. https://doi.org/10.35946/arcr.v40.2.11.CrossRefPubMedPubMedCentral

45.

McDonald JA, Goyal A, Terry MB. Alcohol intake and breast cancer risk: weighing the overall evidence. Curr Breast Cancer Rep. 2013;5(3). https://doi.org/10.1007/s12609-013-0114-z.

46.

De Cicco P, et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019;11:1514.CrossRefPubMedPubMedCentral

47.

Ford KL. CE Orsso, N Kiss, SB Johnson, SA Purcell, A Gagnon, A Laviano, CM Prado Dietary choices after a cancer diagnosis: a narrative review. Nutrition. 2022;103–104:111838. https://doi.org/10.1016/j.nut.2022.111838.CrossRefPubMed

48.

Donini LM, Barrada JR, Barthels F, et al. A consensus document on definition and diagnostic criteria for orthorexia nervosa. Eat Weight Disord. 2022;27(8):3695–711. https://doi.org/10.1007/s40519-022-01512-5. (Erratum in: Eat Weight Disord. 2023 Sep 16;28(1):76).CrossRefPubMedPubMedCentral

49.

Aslan H, Aktürk Ü. Demographic characteristics, nutritional behaviors, and orthorexic tendencies of women with breast cancer: a case-control study. Eat Weight Disord. 2020;25(5):1365–75. https://doi.org/10.1007/s40519-019-00772-y.CrossRefPubMed

50.

Mogal HD, Howard-McNatt M, Dodson R, Fino NF, Clark CJ. Quality of life of older African American breast cancer survivors: a population-based study. Support Care Cancer. 2017;25(5):1431–8. https://doi.org/10.1007/s00520-016-3539-x.CrossRefPubMed

51.

Fenlon D, Frankland J, Foster CL, et al. Living into old age with the consequences of breast cancer. Eur J Oncol Nurs. 2013;17(3):311–6. https://doi.org/10.1016/j.ejon.2012.08.004.CrossRefPubMed

52.

Coughlin SS, Yoo W, Whitehead MS, Smith SA. Advancing breast cancer survivorship among African-American women. Breast Cancer Res Treat. 2015;153(2):253–61. https://doi.org/10.1007/s10549-015-3548-3.CrossRefPubMedPubMedCentral

53.

Page AE, Adler NE (Eds.). Cancer care for the whole patient: meeting psychosocial health needs. National Academies Press. 2008.

54.

Friese CR, Harrison JM, Janz NK, et al. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer. 2017;123(11):1925–34. https://doi.org/10.1002/cncr.30547.CrossRefPubMed

55.

Grant SJ, Hunter J, Seely D, Balneaves LG, Rossi E, Bao T. Integrative oncology: international perspectives. Integr Cancer Ther. 2019;18:1534735418823266. https://doi.org/10.1177/1534735418823266.CrossRefPubMedPubMedCentral

56.

Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203. https://doi.org/10.1177/1534735411423920.CrossRefPubMed

57.

Greenlee H, Balneaves LG, Carlson LE, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. JNCI Monographs. 2014;50:346–58. https://doi.org/10.1093/jncimonographs/lgu041.CrossRef

58.

Lopez G, McQuade J, Cohen L, et al. Integrative oncology physician consultations at a comprehensive cancer center: analysis of demographic, clinical and patient reported outcomes. J Cancer. 2017;8(3):395. https://doi.org/10.7150/jca.17506.CrossRefPubMedPubMedCentral

59.

Witt CM, Balneaves LG, Cardoso MJ, et al. A comprehensive definition for integrative oncology. J Natl Cancer Inst Monogr. 2017;52. https://doi.org/10.1093/jncimonographs/lgx012.

60.

Gannotta R, Malik S, Chan AY, et al. Integrative Medicine as a Vital Component of Patient Care. Cureus. 2018;10(8):e3098. https://doi.org/10.7759/cureus.3098.CrossRefPubMedPubMedCentral

61.

Magno S, Filippone A, Accetta C, et al. Lifestyle counselling and access to integrative treatments in Italian breast centres: Senonetwork national survey. Br J Surg. 2022;109(10):1013–4. https://doi.org/10.1093/bjs/znac166.CrossRefPubMed

62.

Mao JJ, Ismaila N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO Guideline. J Clin Oncol. 2022;40(34):3998–4024. https://doi.org/10.1200/JCO.22.01357.CrossRefPubMed

63.

Ju ZY, Wang K, Cui HS, et al. Acupuncture for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;12:CD012057. https://doi.org/10.1002/14651858.CD012057.pub2.CrossRefPubMed

64.

Molassiotis A, Suen LKP, Cheng HL, et al. A randomized assessor-blinded wait-list-controlled trial to assess the effectiveness of acupuncture in the management of chemotherapy-induced peripheral neuropathy. Integr Cancer Ther. 2019;18:1534735419836501. https://doi.org/10.1177/1534735419836501.CrossRefPubMedPubMedCentral

65.

Wardley AM. ACUFOCIN: Randomized clinical trial of ACUpuncture plus standard care versus standard care alone for chemotherapy induced peripheral neuropathy (CIPN); (12003). In. ASCO Virtual Scientific Program: American Societyof Clinical Oncology 2020. J Clin Oncol. 2020;38(15):12003–12003. https://doi.org/10.1200/JCO.2020.38.15_suppl.12003.CrossRef

66.

Bao T, Patil S, Chen C, et al. Effect of acupuncture vs sham procedure on chemotherapy-induced peripheral neuropathy symptoms: a randomized clinical trial. JAMA Netw Open. 2020;3:e200681. https://doi.org/10.1001/jamanetworkopen.2020.0681.CrossRefPubMedPubMedCentral

67.

Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMOeEONSeEANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020; 31 (10). https://doi.org/10.1016/j.annonc.2020.07.003.

68.

Tsay SL, Chen HL, Chen SC, et al. Effects of reflexotherapy on acute postoperative pain and anxiety among patients with digestive cancer. Cancer Nurs. 2008;31:109–15. https://doi.org/10.1097/01.NCC.0000305694.74754.7b.CrossRefPubMed

69.

Magno S, Cappai E, Dentale F, et al. Effects of plantar reflexology on sleep and quality of life in patients with breast cancer undergoing chemotherapy and hormonal therapies. J Clin Oncol. 2017;35(15). https://doi.org/10.1200/JCO.2017.35.15_suppl.e21697.

70.

Hoffman CJ, Ersser SJ, Hopkinson JB, et al. Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol. 2012;30(12):1335–42. https://doi.org/10.1200/JCO.2010.34.0331.CrossRefPubMed

71.

Henderson VP, Clemow L, Massion AO, et al. The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial. Breast Cancer Res Treat. 2012;131:99–109. https://doi.org/10.1007/s10549-011-1738-1.CrossRefPubMed

72.

Wurtzen H, Dalton SO, Elsass P, et al. Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I-III breast cancer. Eur J Cancer. 2013;49:1365–73. https://doi.org/10.1016/j.ejca.2012.10.030.CrossRefPubMed

73.

Lengacher CA, Reich RR, Paterson CL, et al. Examination of broad symptom improvement resulting from mindfulness-based stress reduction in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2016;34:2827–34. https://doi.org/10.1200/JCO.2015.65.7874.CrossRefPubMedPubMedCentral

74.

Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. https://doi.org/10.1016/j.annonc.2020.09.010.CrossRefPubMed

75.

Zhou K, Li X, Li J, et al. A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: results on depression, anxiety and length of hospital stay. Eur J Oncol Nurs. 2015;19:54–9. https://doi.org/10.1016/j.ejon.2014.07.010.CrossRefPubMed

76.

Wang X, Zhang Y, Fan Y, Tan XS, Lei X. Effects of music intervention on the physical and mental status of patients with breast cancer: a systematic review and meta-analysis. Breast Care. 2018;13(3):183–90. https://doi.org/10.1159/000487073.CrossRefPubMedPubMedCentral

77.

Magno S, Filippone A, Scaldaferri A. Evidence-based usefulness of integrative therapies in breast cancer. Transl Cancer Res. 2018;7:S379–89. https://doi.org/10.21037/tcr.2018.02.06.CrossRef

78.

Pergolotti M, Alfano CM, Cernich AN, et al. A health services research agenda to fully integrate cancer rehabilitation into oncology care. Cancer. 2019;125(22):3908–16. https://doi.org/10.1002/cncr.32382.CrossRefPubMed

79.

Lyons KD, Padgett LS, Marshall TF, et al. Follow the trail: Using insights from the growth of palliative care to propose a roadmap for cancer rehabilitation. CA Cancer J Clin. 2019;69(2):113–26. https://doi.org/10.3322/caac.21549.CrossRefPubMed

80.

Kline-Quiroz C, Nori P, Stubblefield MD. Cancer rehabilitation: acute and chronic issues, nerve injury, radiation sequelae, surgical and chemo-related, Part 1. Med Clin North Am. 2020;104(2):239–50. https://doi.org/10.1016/j.mcna.2019.10.004.CrossRefPubMed

81.

Cheville AL, Mustian K, Winters-Stone K, Zucker DS, Gamble GL, Alfano CM. Cancer rehabilitation: an overview of current need, delivery models, and levels of care. Phys Med Rehabil Clin N Am. 2017;28(1):1–17. https://doi.org/10.1016/j.pmr.2016.08.001.CrossRefPubMed

82.

Sharma R, Molinares-Mejia D, Khanna A, Maltser S, Ruppert L, Wittry S, Murphy R, Ambrose AF, Silver JK. Training and practice patterns in cancer rehabilitation: a survey of physiatrists specializing in oncology care. PM R. 2020;12(2):180–5. https://doi.org/10.1002/pmrj.12196.CrossRefPubMed

83.

Brach M, Cieza A, Stucki G, et al. ICF Core Sets for breast cancer. J Rehabil Med. 2004;(44 Suppl):121–7. https://doi.org/10.1080/16501960410016811.

84.

Irwin ML, Smith AW, McTiernan A, et al. Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study. J Clin Oncol. 2008;26:3958–64.CrossRefPubMedPubMedCentral

85.

Guo W, Fensom GK, Reeves GK, et al. Physical activity and breast cancer risk: results from the UK Biobank prospective cohort. Br J Cancer. 2020;122:726–32. https://doi.org/10.1038/s41416-019-0700-6.CrossRefPubMedPubMedCentral

86.

Santa Mina D, van Rooijen SJ, Minnella EM, et al. Multiphasic prehabilitation across the cancer continuum: a narrative review and conceptual framework. Front Oncol. 2020;10:598425. https://doi.org/10.3389/fonc.2020.598425.CrossRefPubMed

87.

Brahmbhatt P, Sabiston CM, Lopez C, Chang E, Goodman J, Jones J, McCready D, Randall I, Rotstein S, Santa MD. Feasibility of prehabilitation prior to breast cancer surgery: a mixed-methods study. Front Oncol. 2020;25(10):571091. https://doi.org/10.3389/fonc.2020.571091.CrossRef

88.

Toohey K, Hunter M, McKinnon K, Casey T, Turner M, Taylor S, Paterson C. A systematic review of multimodal prehabilitation in breast cancer. Breast Cancer Res Treat. 2023;197(1):1–37. https://doi.org/10.1007/s10549-022-06759-1.CrossRefPubMed

89.

Treanor C, Kyaw T, Donnelly M. An international review and meta-analysis of prehabilitation compared to usual care for cancer patients. J Cancer Surviv. 2018;12(1):64–73. https://doi.org/10.1007/s11764-017-0645-9.CrossRefPubMed

90.

Di Leone A, Terribile D, Magno S, et al. Neoadjuvant chemotherapy in breast cancer: an advanced personalized multidisciplinary prehabilitation model (APMP-M) to optimize outcomes. J Pers Med. 2021;11(5):324. https://doi.org/10.3390/jpm11050324.CrossRefPubMedPubMedCentral

91.

Leclerc AF, Foidart-Dessalle M, Tomasella M, et al. Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. Eur J Phys Rehabil Med. 2017;53(5):633–42. https://doi.org/10.23736/S1973-9087.17.04551-8.CrossRefPubMed

92.

Brick R, Padgett L, Jones J, et al. The influence of telehealth-based cancer rehabilitation interventions on disability: a systematic review. J Cancer Surviv. Published online February 2022;1–26. https://doi.org/10.1007/s11764-022-01181-4.

93.

Cannioto RA, Hutson A, Dighe S, et al. Physical activity before, during, and after chemotherapy for high-risk breast cancer: relationships with survival. J Natl Cancer Inst. 2021;113(1):54–63. https://doi.org/10.1093/jnci/djaa046.CrossRefPubMed

94.

Caperchione CM, Sabiston CM, Stolp S, et al. A preliminary trial examining a “real world” approach for increasing physical activity among breast cancer survivors: findings from project MOVE. BMC Cancer. 2019;19(1):272. https://doi.org/10.1186/s12885-019-5470-2.CrossRefPubMedPubMedCentral

95.

Ruiz-Vozmediano J, Löhnchen S, Jurado L, et al. Influence of a multidisciplinary program of diet, exercise, and mindfulness on the quality of life of stage IIA-IIB breast cancer survivors. Integr Cancer Ther. 2020;19:1534735420924757. https://doi.org/10.1177/1534735420924757.CrossRefPubMedPubMedCentral

96.

de Boer MC, Wörner EA, Verlaan D, van Leeuwen PAM. The mechanisms and effects of physical activity on breast cancer. Clin Breast Cancer. 2017;17(4):272–8. https://doi.org/10.1016/j.clbc.2017.01.006.CrossRefPubMed

97.

Hong BS, Lee KP. A systematic review of the biological mechanisms linking physical activity and breast cancer. Phys Act Nutr. 2020;24(3):25–31. https://doi.org/10.20463/pan.2020.0018.CrossRefPubMedPubMedCentral

98.

Honma N, Makita M, Saji S, Mikami T, et al. Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Support Care Canc: Off J Multinatl Assoc Support Care Canc. 2019;27(10):3813–22.CrossRef

99.

Ugras SK, Rahman RL. Hormone replacement therapy after breast cancer: Yes. No or maybe Mol Cell Endocrinol. 2021;525:111180. https://doi.org/10.1016/j.mce.2021.111180.CrossRefPubMed

100.

Cao C, Friedenreich CM, Yang L. Association of daily sitting time and leisure-time physical activity with survival among US cancer survivors. JAMA Oncol. 2022;8(3):395–403. https://doi.org/10.1001/jamaoncol.2021.6590.CrossRefPubMedPubMedCentral

101.

Dorri S, Asadi F, Olfatbakhsh A, Kazemi A. A systematic review of electronic health (eHealth) interventions to improve physical activity in patients with breast cancer. Breast cancer (Tokyo, Japan). 2020;27(1):25–46. https://doi.org/10.1007/s12282-019-00982-3.CrossRefPubMed

102.

Murri A, Vitucci D, Tranchita E, et al. “OPERATION PHALCO”—adapted physical activity for breast cancer survivors: is it time for a multidisciplinary approach? Cancers. 2022;15(1):34. https://doi.org/10.3390/cancers15010034.CrossRefPubMedPubMedCentral

103.

Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375–90. https://doi.org/10.1249/MSS.0000000000002116.CrossRefPubMedPubMedCentral

104.

Eyigor S, Kanyilmaz S. Exercise in patients coping with breast cancer: an overview. World J Clin Oncol. 2014;5(3):406–11. https://doi.org/10.5306/wjco.v5.i3.406.CrossRefPubMedPubMedCentral

105.

Danhauer SC, Addington EL, Cohen L, et al. Yoga for symptom management in oncology: a review of the evidence base and future directions for research. Cancer. 2019;125(12):1979–89. https://doi.org/10.1002/cncr.31979.CrossRefPubMed

106.

Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of pilates exercises on functional capacity, flexibility, fatigue, depression and quality of life in female breast cancer patients: a randomized controlled study. Eur J Phys Rehabil Med. 2010;46(4):481–7.PubMed

107.

Sprod LK, Janelsins MC, Palesh OG, et al. Health-related quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. J Cancer Surviv: Res Pract. 2012;6(2):146–54. https://doi.org/10.1007/s11764-011-0205-7.CrossRef

108.

Janelsins MC, Davis PG, Wideman L, et al. Effects of Tai Chi Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer survivors. Clin Breast Cancer. 2011;11(3):161–70. https://doi.org/10.1016/j.clbc.2011.03.013.CrossRefPubMedPubMedCentral

109.

Riani Costa LA, Barreto RF, de Leandrini SMM, et al. The influence of a supervised group exercise intervention combined with active lifestyle recommendations on breast cancer survivors’ health, physical functioning, and quality of life indices: study protocol for a randomized and controlled trial. Trials. 2021;22(1):934. https://doi.org/10.1186/s13063-021-05843-z.CrossRefPubMedPubMedCentral

110.

Rogers LQ, Courneya KS, Oster RA, et al. Physical activity intervention benefits persist months post-intervention: randomized trial in breast cancer survivors. J Cancer Surviv: Res Pract. 2023. https://doi.org/10.1007/s11764-022-01329-2. (Advance online publication).CrossRef

111.

Kang H, Moon M. Effects of digital physical activity interventions for breast cancer patients and survivors: a systematic review and meta-analysis. Healthc Inform Res. 2023;29(4):352–66. https://doi.org/10.4258/hir.2023.29.4.352.CrossRefPubMedPubMedCentral

112.

Phillips SM, Penedo FJ, Collins LM, et al. Optimization of a technology-supported physical activity promotion intervention for breast cancer survivors: Results from Fit2Thrive. Cancer. 2022;128(5):1122–32. https://doi.org/10.1002/cncr.34012.CrossRefPubMed

113.

Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial [published correction appears in J Clin Oncol. 2019;37(6):528]. J Clin Oncol. 2016;34(6):557–65.CrossRefPubMed

114.

Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol. 2016;13(5):319–25.CrossRefPubMed

115.

• Di Maio M, Basch E, Denis F, Ripamonti CI, Santini D, on behalf of ESMO Guidelines Committee. The role of patient reported outcomes measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878–92. (This study definitively consecrated the inclusion and the crucial role of patient reported outcomes (PROMs) in clinical practice for all oncology patients.)CrossRefPubMed

116.

Carfora L, Foley CM, Hagi-Diakou P, et al. Patients’ experiences and perspectives of patient-reported outcome measures in clinical care: a systematic review and qualitative meta-synthesis. PLoS One. 2022;17(4):e0267030. https://doi.org/10.1371/journal.pone.0267030.CrossRefPubMedPubMedCentral

117.

Ciotti S, Bianconi F, Saraceni VM, Vulpiani MC, Rinonapoli G, Caraffa A, Zampolini M. Narrative medicine in amyotrophic lateral sclerosis and a rehabilitation project based on international classification of functioning, disability and health. Am J Phys Med Rehabil. 2018;97(11):832–8.CrossRefPubMed

118.

Istituto Superiore di Sanità – Centro Nazionale Malattie Rare. Consensus Conference: “Linee di indirizzo per l’utilizzo della medicina narrativa in ambito clinico- assistenziale, per le malattie rare e cronico-degenerative”. Sole24Ore Sanità, Milano. 2015. www.iss.it/cnmr.

119.

• Cercato MC, Colella E, Fabi A, Bertazzi I, Giardina BG, Di Ridolfi P, Mondati M, Petitti P, Bigiarini L, Scarinci V, Franceschini A, Servoli F, Terrenato I, Cognetti F, Sanguineti G, Cenci C. Narrative medicine: feasibility of a digital narrative diary application in oncology. J Int Med Res. 2022;50(2):3000605211045507. https://doi.org/10.1177/03000605211045507. This study paved the way for a new concept of quality of life measurement. The digital narrative medicine permits to go beyond the classic PROMs, as it helps combining the physical symptoms with emotional distress to provide a better tailored psychophysical profile of our patients.

120.

Cercato MC, Vari S, Maggi G, Faltyn W, Onesti CE, Baldi J, Scotto di Uccio A, Terrenato I, Molinaro C, Scarinci V, Servoli F, Cenci C, Biagini R, Ferraresi V. Narrative medicine: a digital diary in the management of bone and soft tissue sarcoma patients. Preliminary Results of a Multidisciplinary Pilot Study. J Clin Med. 2022;11(2):406. https://doi.org/10.3390/jcm11020406.

121.

Mazzitelli C, Santini D, Corradini AG, et al. Liquid biopsy in the management of breast cancer patients: where are we now and where are we going. Diagnostics (Basel). 2023;13(7):1241. https://doi.org/10.3390/diagnostics13071241.CrossRefPubMed

122.

Ling L, Aldoghachi AF, Chong ZX, et al. Addressing the clinical feasibility of adopting circulating mirna for breast cancer detection, monitoring and management with artificial intelligence and machine learning platforms. Int J Mol Sci. 2022;23(23):15382.CrossRefPubMedPubMedCentral

Title: An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients
Authors: Alessandra Fabi
Alessandro Rossi
Edoardo Mocini
Ludovica Cardinali
Valerio Bonavolontà
Cristina Cenci
Stefano Magno
Vittoria Barberi
Antimo Moretti
Zein Mersini Besharat
Giovanni Iolascon
Carlo Baldari
Elisabetta Ferretti
Andrea Botticelli
Ida Paris
Giovanni Scambia
Silvia Migliaccio
Publication date: 24-02-2024
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Published in: Current Oncology Reports / Issue 4/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01500-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial Registration

Please log in to get access to this content

Other articles of this Issue 4/2024

Head and Neck Mucosal Melanoma: Where Are We Now?

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry

Update on the management of bone metastases

Lymph node dissection in testicular cancer

Novel therapeutic targets in AML

Keynote webinar | Spotlight on antibody–drug conjugates in cancer